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INTRODUCTION
Type II collagen-induced arthritis is a recently described (1, 2) experimental model of autoimmunity in A preliminary account of part of this work was presented at the Annual Meeting ofthe Federation ofAmerican Societies for Experimental Biology, [1] [2] [3] [4] [5] [6] [7] [8] April 1977, Chicago, Ill.
Received for publication 11 November 1977 and in revised form 14 April 1978. rats, produced by intradermal injection of a distinct type of collagen found in cartilage (type II collagen). Many features of this model, such as its proliferative synovitis, closely resemble rheumatoid arthritis (1, 2) . The arthritis exhibits a specificity for native type II collagen, as immunization with type I and III collagens prepared from skin or the denatured a-chains comprising type II do not cause disease. Moreover, type II collagens extracted from human, chick, or rat cartilage are all arthritogenic (1) . Previous animal models of autoimmunity to a tissue component require use of adjuvant oil containing bacterial preparations to regularly induce disease (3) . In contrast, the incidence and severity of arthritis (1) or magnitude of humoral or cellular sensitivity to type II collagen (2) in this disease is the same whether complete Freund's adjuvant (CFA)l or incomplete Freund's adjuvant (ICFA; Difco Laboratories, Detroit, Mich.) is used. This property, i.e., the ability of heterologous or homologous type II collagen emulsified in ICFA to induce arthritis in -40% of several strains of rats, demonstrates the uniqueness of this protein in evoking an autoimmune response. It also indicates that this collagen-induced arthritis is distinct from the previously described adjuvant disease in the rat, which is induced by intradermal injection of CFA (1) .
That immunologic mechanisms might be involved in the causation of type II collagen-induced arthritis was initially suggested by the dense infiltration of the synovium of arthritic joints by mononuclear cells (1) .
Also consistent with this hypothesis was the finding that the magnitude of both humoral and cellular sensitivity to type II collagen correlated with the occurrence of arthritis in rats injected intradermally with this protein (2) . Passive transfer of type II collageninduced arthritis with cells, described in this paper, Histocompatibility evaluation. Histocompatibility of the W/L strain was tested by duration of survival of full thickness skin grafts (4) and MLC (5) . To perform the MLC, blood was obtained by cardiac puncture from W/L or Wistar rats, and mononuclear cells were isolated and cultured by a microtechnique we have previously described (2 (6) . To assess this potential, experiments involving a popliteal lymph node weight assay in rats (7) were performed. 10-to 12-wkold W/L rats received subcutaneous injections of 9 x 106 W/L splenocytes suspended in 0.1 ml sterile phosphate-buffered saline in the right volar hindpaw and the same volume ofphosphate-buffered saline alone on the left. Total popliteal lymph node weight was then determined on both sides when the recipients were killed 7 days later. GVH reactivity would be expected to increase the weight of the responding nodes on the right (7).
Collagens. Native type I and II collagens were solubilized from lathyritic chick skin and sterna, respectively, and purified by methods previously described (1) . Purity was confirmed by uronic acid assay, carboxymethylcellulose chromatography, and amino acid analvsis (1) .
Sensitizations. Donor rats were injected intradermally with 0.5 mg of type II collagen dissolved in 0.5 ml 0.1 M acetic acid at 40C and emulsified in 0.5 ml cold ICFA, as previously described (1) . Control rats were sensitized in the same manner with an identical amount of type I collagen. Other control donors received intradermal injections ofthe acetic acid without collagen in ICFA. CFA was not employed in these experiments because this agent is capable of inducing an arthritis in rats on its own accord (1).
Antibody quantitation. Sera were tested for antibodies to type I or II collagen by passive microhemagglutination using human (group 0, Rh+) erythrocytes fixed by glutaraldehyde and sensitized with collagen, as we have previously described (2) . Titers, after comparison to those of reference antisera and to sera from control rats not sensitized with collagen, were expressed as -log2 units.
Quantitation of cellular sensitivity to collagen. Cellular sensitivity to type II collagen was assayed by antigen-induced [3H]TdR incorporation in vitro by blood mononuclear cells cultured in quadruplicate by a microtechnique which we have previously described (2) . Like the MLC, all assays included phytohemagglutinin-stimulated cells as a control.
Cell transfers. Rats were sacrificed by ether anesthesia either 11-21 days after injection of type II collagen or after the onset of clinically recognizable arthritis (11-28 days postinjection). Control rats injected with type I collagen or ICFA alone were sacrificed at 11-21 days. Cells from uninjected rats ofthe same age provided an additional control. The spleen and cervical and inguinal lymph nodes were removed using sterile technique and placed in Hanks' balanced salt solution (HBSS, Microbiological Associates). The pooled spleen and lymph nodes were thoroughly teased, and cells were aspirated off, washed three times in HBSS, counted with a Coulter Counter (Coulter Electronics, Inc., Hialeah, Fla.), and tested for viability by exclusion of 0.2% trypan blue. Suspensions of 6-10 x 108 cells in 1.5 ml HBSS were then slowly injected into a tail vein of recipient rats.
As an antigen control, collagen was added to pools of cells from some rats injected with ICFA. To accomplish this, type II collagen was dissolved at a concentration of 1.0 mg/ml in 0.1 M acetic acid at 4°C for 48 h. The collagen was next dialyzed for 24 h at 40C against 0.1 M calcium acetate and then cold HBSS for the final 4 h before administration. 0.5 ml of the collagen solution was then added to the cell suspension immediately before intravenous injection. Exclusion oftrypan blue confirmed that cells remained viable after the addition of collagen. Heat-killed sensitized cells provided an additional antigen control. Falcon 3033 tubes (Falcon Plastics, Div. of BioQuest, Oxnard, Calif.) containing suspensions of 8 x 108 cells from arthritic rats injected with type II collagen were immersed in boiling water for 3 min immediately before intravenous injection. Although the cells remained intact, all cells were stained by trypan blue after this procedure. Serum transfers. Blood was obtained by cardiac puncture from type II collagen-immunized donors that were arthritic at the time they were sacrificed. Sera were pooled and stored at -70°C. After thawing and determining antibody titers to type II collagen, 3.0-ml aliquots were injected i.v. into recipient rats.
Clinical evaluation. Clinical examination for arthritis was conducted daily. Severity was quantified by a conventional arthritic index in which limbs were graded 0 to 4, representing increasing erythema and swelling and by measurement of the intermalleolar thickness of the ankle by the same observer with a constant tension caliper (B. C. Ames, Co., Waltham, Mass.). Both techniques were previously described (1) . The reproducibility of the caliper measurements was determined by comparing readings performed in a blind fashion on 2 successive days. Analysis of 105 ankle measurements in normal age-matched W/L rats yielded an intermalleolar thickness of 6.4±0.1 mm (mean±SEM) with an estimated intraobserver average error (8) of 0.3 mm for two individual readings. Presence of arthritis in recipients was always confirmed by a blind technique utilizing different evaluators outside ofthe investigators' study group. This was done by mixing an arthritic rat with three nonarthritic rats before presentation to two independent evaluators, who were asked to identify any that had both redness and swelling of at least one hindlimb. Occasionally, observers were presented with four nonarthritic rats.
Histologic evaluation. Recipients of experimental and control cells were sacrificed 21 days after transfer, and their ankles were processed for histologic examinations, as previously described (1) . Ankles of rats receiving arthritic sera were evaluated after sacrificing 10 days post-transfer. Cross sections of the ankle, stained with hematoxylin and eosin, were randomized and coded to allow examination by a blind technique for evidence of synovial inflammation by light microscopy. Presence of synovitis was independently confirmed in all recipients by a pathologist (Dr. John Caulfield).
Roentgenographic evaluation. Hindlimbs of recipients were evaluated radiographically for soft-tissue swelling and joint destruction by methods previously described (1).
Immunologic evaluation. Sera from all rats receiving cells or serum were tested for hemagglutinating antibodies to the appropriate collagen at the time of sacrifice. Recipients that became arthritic were tested for cellular sensitivity to type II collagen by [3H]TdR incorporation studies using blood mononuclear cells obtained at sacrifice.
RESULTS
Histocompatibility of W/L rats and absence of GVH reactivity. Histocompatibility of these W/L rats was confirmed by skin graft acceptance and MLC testing. Cell transfer of arthritis. Table I shows the results of our cell transfer studies for both experimental and control groups. 9 of 32 (28%) rats receiving cells from donors injected with type II collagen developed clinically apparent arthritis. If only those rats receiving cells from pools at least partially comprised of arthritic donors are considered, 4 of 10 transfers resulted in arthritis. All nine arthritic rats were correctly identified by the observers outside of the investigators' study group. No rats were erroneously adjudged to be arthritic by these evaluators. In contrast, Table I also indicates that arthritis failed to develop in control groups employing a total of 97 recipients. Thus, the incidence of arthritis in the experimental group was highly significant (P < 0.0001 by chi-square analysis) when compared to the absence of arthritis in the control group.
Controls examined included recipients of cells from unimmunized donors, recipients of cells from donors injected with ICFA alone, recipients of cells from donors injected with type I collagen in ICFA, recipients of cells from ICFA-injected donors to which solu- (Fig. 1 ). Limbs were also graded 0 to 4 by a conventional arthritic index. Involved limbs in arthritic donors were consistently scored 4 at the time of sacrifice (Fig. 2) . Disease transferred by cells displayed milder features with a mean score of 2.3+0.2 for the 16 involved limbs (Fig.  3) . All joints in the recipients that were considered arthritic had an index of 2 or 3.
Inflammation persisted for at least 2 wk (Fig. 4) . All joints from the arthritic recipients were evaluated histologically at sacrifice approximately 2 wk after the onset of disease and showed active synovitis, consisting of hyperplasia of the synoviocytes and infiltration by numerous mononuclear cells (Fig. 5) . Only minimal bone and cartilage destruction was found. Joint radiographs performed in six of the nine arthritic recipients at sacrifice showed soft-tissue swelling of the hindlimbs but no bone erosion or periostitis.
Evaluation of arthritic recipients for humoral and cellular sensitivity to type II collagen. Evidence of humoral and cellular responses to type II collagen differed in arthritic donors and recipients. In contrast to server without knowledge ofprevious values on the days indicated after receipt of cells. Arthritis was first apparent in the experimental recipient (arrow) on day 6 and was bilateral at that time. Numbers adjacent to experimental caliper measurements represent arthritic index. All appraisals of the control rat merited an index score of 0. It is apparent that arthritis persisted for 3 wk until sacrifice in the recipient of sensitized cells. (9) , and cornea (10) of the eye. We have recently shown (1) that native collagen extracted from cartilage is arthritogenic for rats. Inasmuch as this collagen has the chromatographic characteristics and amino acid composition previously described for type II collagen (11) , we assume that type II collagen is the arthritogenic moiety in our preparations. Both type I and II collagens can induce typespecific humoral (12) and cellular (2) (14) . Transfer experiments involving Tor B-cell-depleted populations, sensitized cells suspended in arthritic serum, and large quantities of antibodies to type II collagen are in progress. These studies may further characterize the cells responsible for this arthritis.
It was of interest that although the W/L rats used in these experiments were demonstrated to be histocompatible, on the basis of skin graft survival and MLC testing, clinically apparent arthritis could be induced in only -40% of these rats by either primary injection of type II collagen (1) or transfer of cells from arthritic donors. The explanation for this is presently unknown but worth pursuing.
In these experiments, cells from both arthritic and clinically disease-free donors were capable ofpassively transferring arthritis. Our data might be interpreted to indicate that the development of arthritis in the donor was not a requisite for successful cell transfer of the disease. However, we would caution that cells from nonarthritic donors were obtained 11-21 days after injection ofcollagen. Because clinically apparent arthritis in the primary disease occasionally did not begin until the 4th wk after injection, it is likely that these transfers included cells from prearthritic donors; this could explain the successful induction of arthritis by cells from disease-free donors. It is also probable that sensitized cells from arthritic donors were diluted by pooling with cells from disease-free donors in some experiments. This might partially account for the low incidence of successful transfer of arthritis.
In conclusion, type II collagen-induced arthritis can be passively transferred by sensitized spleen and lymph node cells. This implies that immunologic hypersensitivity to the cartilage type of collagen initiates this autoimmune disease. Additional studies, however, are required to determine the precise role of T and B cells in the pathogenesis of the proliferative synovitis present in this animal model.
